AIDS Weekly Plus
New HIV/AIDS Study Findings Recently Were Published by Researchers at University of Massachusetts School of Medicine
September 10, 2012
2012 SEP 10 (NewsRx) -- By a News Reporter-Staff News Editor at AIDS Weekly -- Researchers detail new data in HIV/AIDS. According to news reporting originating from Worcester, Massachusetts, by NewsRx correspondents, research stated, "The human immunodeficiency virus 1 (HIV-1) virion infectivity factor (Vif) protein, essential for in vivo viral replication, protects the virus from innate antiviral cellular factor apolipoprotein B mRNA-editing, enzyme-catalytic, polypeptide-like 3G (APOBEC3G; A3G) and is an attractive target for the development of novel antiviral therapeutics. We have evaluated the structure-activity relationships of N-(2-methoxyphenyl)-2-((4-nitrophenyl)thio)benzamide (RN-18), a small molecule recently identified as an inhibitor of Vif function that blocks viral replication only in nonpermissive cells expressing A3G, by inhibiting Vif-A3G interactions."
Our news editors obtained a quote from the research from the University of Massachusetts School of Medicine, "Microwave-assisted cross-coupling reactions were developed to prepare a series of RN18 analogues with diverse linkages and substitutions on the phenyl rings. A dual cell-based assay system was used to assess antiviral activity against wild-type HIV-1 in both nonpermissive (H9) and permissive (MT4) cells that also allowed evaluation of specificity. In general, variations of phenyl substitutions were detrimental to antiviral potency and specificity, but isosteric replacements of amide and ether linkages were relatively well tolerated."
According to the news editors, the researchers concluded: "These structure-activity relationship data define structural requirements for Vif-specific activity, identify new compounds with improved antiviral potency and specificity, and provide leads for further exploration to develop new antiviral therapeutics."
For more information on this research see: Synthesis and structure-activity relationship studies of HIV-1 virion infectivity factor (Vif) inhibitors that block viral replication. Chemmedchem, 2012;7(7):1217-29. (Wiley-Blackwell - www.wiley.com/; Chemmedchem - onlinelibrary.wiley.com/journal/10.1002/(ISSN)1860-7187)
The news editors report that additional information may be obtained by contacting A. Ali, Chemical Biology Program, Dept. of Biochemistry and Molecular Pharmacology, University of Massachusetts Medical School, 364 Plantation Street, Worcester, MA 01605, United States (see also HIV/AIDS).
Keywords for this news article include: HIV/AIDS, Worcester, RNA Viruses, Retroviridae, Massachusetts, United States, HIV Infections, Vertebrate Viruses, Primate Lentiviruses, North and Central America, Human Immunodeficiency Virus, Viral Sexually Transmitted Diseases.
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2012, NewsRx LLC